US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial

Filana Therapeutics

26/09/2024 22:43

WASHINGTON, Sept 26 (Reuters) - The U.S. Securities and
Exchange Commission said on Thursday that it charged Cassava
Sciences  SAVA.O  and two of the company's former executives for
misleading claims about the results of Alzheimer’s clinical
trials.
    The SEC said the company's founder and former CEO, Remi
Barbier, and its former senior vice president of neuroscience,
Dr. Lindsay Burns, will pay more than $40 million to settle
charges.

 (Reporting by Jasper Ward
Editing by Chris Reese)
 ((Jasper.Ward@thomsonreuters.com;))